Leaders in Pharmaceutical Business Intelligence (LPBI) Group

9:40 am – 10:30 am 3/27/2015 Better Business Track: The Evolving Reimbursement Landscape @ MassBio Annual Meeting 2015, Cambridge, MA, Sonesta Hotel, 3/26 – 3/27, 2015

Dr. Aviva Lev-Ari will be in attendance on March 26, 2015, 8:00AM to March 27, 2015, 2:00PM

Leaders in Pharmaceutical Business Intelligence are Covering the Event in REALTIME using Social Media

http://pharmaceuticalintelligence.com

Panelists:

• Steve Haas, Vice President, Evidence & Value Demonstration, Genzyme

1. How disease affect the Patient,
2. project Clinical Trial Results
3. Disease state Economics, Utilization of Services and ability to be employed if ill
4. Patient reported information reported by Patients
5. Early advice and Partner with Health Technology Assessment
6. Price control came out from ACA — evaluation of therapies by effectiveness
7. Price at time of launch
8. Society vs Patient benefits vs National Budget of HealthCare

• Meridith Johnson, Director, Health Economics & Outcomes Research, GE Healthcare

1. Payer brought inside during a diagnostics development
2. Payers need to see outcomes
3. Value of diagnostics and of drugs
4. Indirect element – Technology assessment – Cost and Effect — In the UK done routinely
5. burden taking to Payers
6. At the regulatory level — no improved efficacy demonstrated — waste of developemnt resources

• Steve Miller, Senior Vice President & Chief Medical Officer, Express Scripts – 85 Million members and 25 Millions of Medical Claims data – Data mining of Drug used and Drug Prescription

1. Clinical Includes: first for product evaluation
2. Clinical Excluded: Substibute Statins
3. Options: 85% on the Formularea are — Several Penicilins — negotiation of Price
4. Pricing power of Biotech companies in the Marketplace
5. Keep US at cutting edge for Drugs and Devices and DIagnostics  – Payers in the US are very concerned obout costs of therapies
6. Savaldi for HepC — $140,000 x 3.2 Millions HepC patients — No One drug threaten the Gov’t Healthcare budget – payer outcome vs the Budget in Total
7. no single product be more that 1% of the entire budget
8. Cancer drug for pancreatic cancer – prolongs life with 12 days, same drug prolongs lung cancer patient’s life by one year — SHOULD BOTH PATIENT PAY SAME AMOUNT FOR THIS DRUG?
9. Reimbursement by VALUE of the drug – strategy for Payers
10. Antibiotics – innovation vs infrequent use minimal reimbursement — WOrking with Gov’t to develop new antibiotics
11. NIH — is the KEY IN DEVELOPMENT AND FUNDING THE RESEARCH LEADING TO INNOVATIONS IN DRUGS
12. Antibiotics in the generic market
13. Data repository: FInd the population at risk in UK a sealing on Price, in the US the level field id Medicare price then price increase to the roof

• Lowell Schnipper, Chief, Division of Hematology and Oncology at Beth Israel Deaconess Medical Center

1. ESCO – Value
2. Cancer MDs – Oncologist Guidelines — Doctor’s Obligation of the financial burden on Patients when a drug is presctibes.
3. Cancer is existential thretening disease. Patients and Physicians are affected by decisions made
4. Accent on COst is inappropriate — VALUE need be the criteria, assess value task force
5. Making Uniques drugs to be available to Patient, transfer from Payer to Patients, Toll of 50% of income to defray the cost of Cancer for Patients with this diagnosis
6. Providers: Use combination – Pathways coming out from Medical Center, Outcomes for $
7. Savaldi – prevents liver transplant it is a cure vs Oncology Neoplastic agents that in comparison do not contribute to SOciety vs a growth hormone to a Child — allowing him to grow as a productive member of society
8. Providers push back Sloan Keterring – decline  a drug for colon cancer – not effective — cost was the reason
9. Esco vs Kettering — not same Perspective
10. Provides MD Anderson and SLoan-Kettering — move away in reimbursement — QUALITY is now getting into the vanguard
11. How can we deign systemn to optimize outcome and preserve innovations and cost effectiveness
12. drugs are introduced TOO late in the course of the disease, thus, value is small
13. Reecptin in early stage has great value not so in late stage
14. VALUE-BASED PRICING – pay for colonoscopy it saves life — the population benefit – PAy if outcome favorable donot pay if not — like in the UK
15. Individual Approach: Private and Public Panel and FDA and the complete dispersal — valuing the agents — METOO DRUGS is a problem down the road when BVALUE ABD OUTCOMES are measured
16. Innovation to avoid development of Me Too drugs

Moderator:

• Leora Schiff, Principal, Altius Strategy Consulting

1. Cancer Drug COst – Perspective on Immunotherapy